Immuno Oncology 2017: Press & Media

We welcome media interested in obtaining information and reporting on cancer issues. Registration for ESMO Immuno Oncology 2017 is free to bona fide journalists on presentation of a letter of assignment and a valid press card.

Media representatives are required to observe and abide by the ESMO Media Policy.

Press Conference

Official ESMO Immuno Oncology Congress Press Conference, Thursday 7 December at 12:15 CET

  • The role of immunotherapy in the armamentarium of oncologists: what works, where and for whom, Rolf Stahel
  • Innovative research which may be the key to understanding why only a limited number of patients respond to checkpoint inhibitors today, Laurence Zitvogel
  • LBA1_PR: Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150), Martin Reck
  • LBA1_PR: An important advancement in the use of immunotherapy in first-line treatment of metastatic NSCLC?, Solange Peters
  • Immunotherapy: with or without side-effects? Which ones? How to deal with them? John Haanen
  • First-of-its-kind analysis of the global immuno-oncology clinical landscape from pre-clinical development to regulatory approval, Aiman Shalabi
  • Cancer immunotherapy is here to stay: can we afford it? The role of philanthropy in supporting immuno-oncology, George Coukos

ESMO Immuno Oncology 2017 Congress - Press Conference

Media registration

To register for ESMO Immuno Oncology 2017, please complete the media registration form. Media registration in advance is strongly recommended although on-site registration will be possible.

Complete the Media Registration Form

Programme and abstracts

For details about the Official ESMO Immuno Oncology 2017 Programme and Abstracts, please click here.

Publication of accepted abstracts

Abstracts accepted for presentation at ESMO IO 2017 as Proffered Paper (oral presentation, suffix 'O'), Poster Discussion (suffix 'PD') and Poster (suffix 'P') will be published online on the ESMO website at 12:00 CET on Monday, 4 December 2017.

Abstracts 5O_PR and 8O_PR, selected for the official ESMO IO 2017 Press Programme, will be made public at the beginning of the official Congress session during which they are presented.

Abstract LBA1_PR, selected for the official ESMO IO 2017 Press Programme, will be made public at 07:00 am CET on Thursday, 7 December 2017

All accepted abstracts will be published in the ESMO Immuno Oncology Congress 2017 Abstract Book, a supplement of the official ESMO journal Annals of Oncology.

Further information for press representatives will be made available over the coming months. Please contact the ESMO Press Office for any additional question.

Contact

ESMO Press Office

E-mail: media@esmo.org